Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Risk of developing tuberculosis disease among persons diagnosed with latent tuberculosis infection in the Netherlands.

Erkens CG, Slump E, Verhagen M, Schimmel H, Cobelens F, van den Hof S.

Eur Respir J. 2016 Nov;48(5):1420-1428. doi: 10.1183/13993003.01157-2016. Epub 2016 Oct 6.

2.

Monitoring latent tuberculosis infection diagnosis and management in the Netherlands.

Erkens CG, Slump E, Verhagen M, Schimmel H, de Vries G, Cobelens F, van den Hof S.

Eur Respir J. 2016 May;47(5):1492-501. doi: 10.1183/13993003.01397-2015. Epub 2016 Feb 25. Erratum in: Eur Respir J. 2017 Jan 25;49(1):.

3.

[Tuberculosis among asylum-seekers in the Netherlands: a descriptive study among the two largest groups of asylum-seekers].

de Vries G, Gerritsen RF, van Burg JL, Erkens CG, van Hest NA, Schimmel HJ, van Dissel JT.

Ned Tijdschr Geneeskd. 2016;160:D51. Dutch.

PMID:
26980468
4.

The epidemiology of childhood tuberculosis in the Netherlands: still room for prevention.

Erkens CG, de Vries G, Keizer ST, Slump E, van den Hof S.

BMC Infect Dis. 2014 May 31;14:295. doi: 10.1186/1471-2334-14-295.

5.

Extent and origin of resistance to antituberculosis drugs in the Netherlands, 1993 to 2011.

Ruesen C, van Gageldonk-Lafeber AB, de Vries G, Erkens CG, van Rest J, Korthals Altes H, de Neeling H, Kamst M, van Soolingen D.

Euro Surveill. 2014 Mar 20;19(11). pii: 20738.

6.

Added value of interferon-gamma release assays in screening for tuberculous infection in the Netherlands.

Erkens CG, Dinmohamed AG, Kamphorst M, Toumanian S, van Nispen-Dobrescu R, Alink M, Oudshoorn N, Mensen M, van den Hof S, Borgdorff M, Verver S.

Int J Tuberc Lung Dis. 2014 Apr;18(4):413-20. doi: 10.5588/ijtld.13.0589.

PMID:
24670695
7.

Tuberculosis treatment outcome monitoring in European Union countries: systematic review.

van Hest R, Ködmön C, Verver S, Erkens CG, Straetemans M, Manissero D, de Vries G.

Eur Respir J. 2013 Mar;41(3):635-43. doi: 10.1183/09031936.00030612. Epub 2012 Jul 12. Review.

8.

Coverage and yield of tuberculosis contact investigations in the Netherlands.

Mulder C, van Deutekom H, Huisman EM, Meijer-Veldman W, Erkens CG, van Rest J, Borgdorff MW, van Leth F.

Int J Tuberc Lung Dis. 2011 Dec;15(12):1630-7. doi: 10.5588/ijtld.11.0027.

PMID:
22118170
9.

Missed opportunities in tuberculosis control in The Netherlands due to prioritization of contact investigations.

Mulder C, Erkens CG, Kouw PM, Huisman EM, Meijer-Veldman W, Borgdorff MW, van Leth F.

Eur J Public Health. 2012 Apr;22(2):177-82. doi: 10.1093/eurpub/ckr017. Epub 2011 Mar 7.

PMID:
21382971
10.

Tuberculosis contact investigation in low prevalence countries: a European consensus.

Erkens CG, Kamphorst M, Abubakar I, Bothamley GH, Chemtob D, Haas W, Migliori GB, Rieder HL, Zellweger JP, Lange C.

Eur Respir J. 2010 Oct;36(4):925-49. doi: 10.1183/09031936.00201609.

11.

Projection of the number of patients with tuberculosis in the Netherlands in 2030.

van Leth F, Kalisvaart NA, Erkens CG, Borgdoff MW.

Eur J Public Health. 2009 Aug;19(4):424-7. doi: 10.1093/eurpub/ckp042. Epub 2009 Apr 8.

PMID:
19357241
12.

[Estimation of the incidence of tuberculosis in The Netherlands in 2030].

van Leth F, Kalisvaart NA, Erkens CG, Borgdorff MW.

Ned Tijdschr Geneeskd. 2008 Mar 15;152(11):616-21. Dutch.

PMID:
18410022

Supplemental Content

Loading ...
Support Center